Drug intelligence / Profile preview

Buqi Jiedu

Development stage: Preclinical
Lead developer: Dongzhimen Hospital of Beijing University of Traditional Chinese Medicine
Administration: Oral

Overview

Buqi Jiedu is a traditional Chinese medicine (TCM) decoction under investigation for its therapeutic effects in conditions characterized by "qi deficiency and poisoning syndrome." It is being studied in clinical trials for indications such as carotid atherosclerotic plaque ulcer and diabetic foot ulcer. The development of this decoction involves entities like the National Science and Technology Major Project and Dongzhimen Hospital, Beijing University of Chinese Medicine.

Other names: Buqi Jiedu Decoction补气解毒汤

Beyond the preview

Go deeper on Buqi Jiedu.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Buqi Jiedu.

Explore the full profile